RT Journal Article
SR Electronic
T1 Robust clinical detection of SARS-CoV-2 variants by RT-PCR/MALDI-TOF multi-target approach
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.09.21263348
DO 10.1101/2021.09.09.21263348
A1 Hernandez, Matthew M.
A1 Banu, Radhika
A1 Gonzalez-Reiche, Ana S.
A1 van de Guchte, Adriana
A1 Khan, Zenab
A1 Shrestha, Paras
A1 Cao, Liyong
A1 Chen, Feng
A1 Shi, Huanzhi
A1 Hanna, Ayman
A1 Alshammary, Hala
A1 Fabre, Shelcie
A1 Amoako, Angela
A1 Obla, Ajay
A1 Alburquerque, Bremy
A1 Helena Patiño, Luz
A1 Ramírez, Juan David
A1 Sebra, Robert
A1 Gitman, Melissa R.
A1 Nowak, Michael D.
A1 Cordon-Cardo, Carlos
A1 Schutzbank, Ted E.
A1 Simon, Viviana
A1 van Bakel, Harm
A1 Sordillo, Emilia Mia
A1 Paniz-Mondolfi, Alberto E.
YR 2021
UL http://medrxiv.org/content/early/2021/09/16/2021.09.09.21263348.abstract
AB The COVID-19 pandemic sparked rapid development of SARS-CoV-2 diagnostics. However, emerging variants pose the risk for target dropout and false-negative results secondary to primer/probe binding site (PBS) mismatches. The Agena MassARRAY® SARS-CoV-2 Panel combines RT-PCR and MALDI-TOF mass-spectrometry to probe for five targets across N and ORF1ab genes, which provides a robust platform to accommodate PBS mismatches in divergent viruses. Herein, we utilize a deidentified dataset of 1,262 SARS-CoV-2-positive specimens from Mount Sinai Health System (New York City) from December 2020 through April 2021 to evaluate target results and corresponding sequencing data. Overall, the level of PBS mismatches was greater in specimens with target dropout. Of specimens with N3 target dropout, 57% harbored an A28095T substitution that is highly-specific for the alpha (B.1.1.7) variant of concern. These data highlight the benefit of redundancy in target design and the potential for target performance to illuminate the dynamics of circulating SARS-CoV-2 variants.Competing Interest StatementRobert Sebra is VP of Technology Development and a stockholder at Sema4, a Mount Sinai Venture. This work, however, was conducted solely at Icahn School of Medicine at Mount Sinai. Otherwise, the authors declare no competing interests.Funding StatementThe Research reported in this paper was supported by the National Institutes of Health (NIH) contract number HHSN272201400008C, the NIH Office of Research Infrastructure under award numbers S10OD018522 and S10OD026880, institutional and philanthropic funds (Open Philanthropy Project, #2020-215611), as well as a Robin Chemers Neustein Postdoctoral Fellowship Award (to Dr. Gonzalez-Reiche).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Institutional Review Board of the Icahn School of Medicine at Mount Sinai (HS#13-00981).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSARS-CoV-2 sequencing read data for all study genomes were deposited in GISAID [www.gisaid.org] (accessions pending).